If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
59.80    1.60 (2.81%)
Bid:
57.20
Ask:
60.00
Spread: 2.80 (4.895%)
Market Cap: £48.70m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Update

27 Mar 2008 07:02

Flomerics Group PLC27 March 2008 Flomerics Group PLC ("Flomerics" or "the Company") Update Flomerics, the global supplier of specialist simulation software for electronicsand fluid flow simulation, is today providing an update on its operational plansand outlook for 2008 and beyond in the light of the recent changes inshareholdings in the Company. Flomerics' strategy remains to be a leading provider of software simulationsolutions to the worldwide engineering design market. Flomerics' softwaresolutions are targeted at the world electronic thermal management and fluid flowsoftware markets. These markets are growing strongly and the Company believes it has significantopportunities for growth. For example, data published by Global IndustryAnalysts, Inc.(1) indicates that the world electronic thermal managementsoftware market will continue to grow by 10% per year over the next five years.The Company's electronics cooling business is well positioned to benefit fromthis growth, particularly in Asia and the Far-East, which has seen strong growthin recent years. Similarly, the computer-aided engineering industry is expected to grow at acompound annual growth rate of 12% through 2009(2). The Board believesFlomerics' products can outperform this average market growth rate due to thecompetitive advantages offered by its products. Strong growth has already beenseen for the Engineering Fluid Dynamics (EFD) product range in 2007 and into2008. The investment in sales and marketing in 2007, aimed at accelerating revenuegrowth particularly from the EFD product range (acquired as part of theacquisition of Nika GmbH in 2006) is beginning to show positive results. Thisreinforces the Board's confidence that 2008 revenues will show considerableimprovement over 2007. Flomerics has cash balances of approximately Β£5.0m compared to Β£2.7m as at 31December 2007, and the Company is well funded to undertake the investment neededto deliver its strategy. Following on from the acquisitions of MicReD in 2005and Nika GmbH in 2006, additional growth through targeted acquisition remains animportant focus for the Company. The board continues to review potentialcandidates against its strategic and financial targets. The Company expects to announce its preliminary results for 2007 on 29 April. Enquiries: Flomerics Group plc +44 20 8487 3000Gary Carter, Chief ExecutiveKeith Butcher, Finance Director Conduit PR +44 20 7429 6604Christian Taylor-Wilkinson, Charlie Geller +44 7970 067320 Oriel Securities Limited +44 20 7710 7600Nominated AdviserDavid ArchAndrew Edwards For further details regarding the source information used in this announcementplease contact Charlie Geller, Conduit PR, on 0207 429 6604 -------------------------- (1) Source: PRWeb(2) Source: Daratech Inc This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Apr 202010:01 amRNSUpdate on Results Announcements
16th Apr 202012:48 pmRNSIssue of Equity and Total Voting Rights
2nd Apr 20207:00 amRNSBusiness Update - COVID-19;Notice of Final results
27th Mar 20202:46 pmRNSDirectorate Changes
6th Mar 202012:15 pmRNSHolding(s) in Company
17th Feb 20207:00 amRNSDirector/PDMR Shareholding
14th Feb 20203:12 pmRNSHolding(s) in Company
13th Feb 20203:58 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNS2019 Trading update & restructuring activities
7th Feb 20204:44 pmRNSHolding(s) in Company
6th Feb 20206:07 pmRNSHolding(s) in Company
20th Jan 20204:13 pmRNSHolding(s) in Company
15th Jan 20204:38 pmRNSHolding(s) in Company
14th Jan 20207:00 amRNSTrading Update - for the year to 31 December 2019
17th Dec 20195:43 pmRNSHolding(s) in Company
5th Dec 20194:41 pmRNSSecond Price Monitoring Extn
5th Dec 20194:35 pmRNSPrice Monitoring Extension
2nd Dec 20194:40 pmRNSSecond Price Monitoring Extn
2nd Dec 20194:35 pmRNSPrice Monitoring Extension
27th Nov 20191:51 pmRNSDirector/PDMR Shareholding
25th Nov 20194:40 pmRNSSecond Price Monitoring Extn
25th Nov 20194:35 pmRNSPrice Monitoring Extension
22nd Nov 20194:40 pmRNSSecond Price Monitoring Extn
22nd Nov 20194:35 pmRNSPrice Monitoring Extension
30th Oct 20199:30 amRNSDirector Share Option Award
28th Oct 20197:00 amRNSDirector/PDMR Shareholding
22nd Oct 20197:00 amRNSTrading update -nine month period to 30 Sept 2019
30th Sep 20194:10 pmRNSCorrection: Director/PDMR Shareholding
30th Sep 201911:32 amRNSDirector/PDMR Shareholding
24th Sep 20197:00 amRNSHalf-Year Report - six months ended 30 June 2019
15th Aug 20191:56 pmRNSDirector/PDMR Shareholding
14th Aug 201912:08 pmRNSSecond Price Monitoring Extn
14th Aug 201912:02 pmRNSPrice Monitoring Extension
30th Jul 20197:00 amRNSIssue of Equity and Total Voting Rights (TVR)
18th Jul 201911:29 amRNSDirector/PDMR Shareholding
16th Jul 201912:07 pmRNSSecond Price Monitoring Extn
16th Jul 201912:02 pmRNSPrice Monitoring Extension
12th Jul 20197:00 amRNSGroup Trading Update & Notice of Half-Year results
13th Jun 201911:25 amRNSIssue of Equity and Total Voting Rights
5th Jun 201910:56 amRNSResults of Voting AGM - 5 June 2019 and TVR
5th Jun 20198:46 amRNS2019 Annual General Meeting Statement
16th May 20197:00 amRNSDeferred Consideration and Total Voting Rights
8th May 20191:35 pmRNSAudited Results - Notice of Annual General Meeting
7th May 201911:34 amRNSHolding(s) in Company
17th Apr 20195:21 pmRNSHolding(s) in Company
16th Apr 20197:00 amRNSPreliminary results - year ended 31 December 2018
16th Apr 20197:00 amRNSQ1 2019 Trading Update
8th Apr 20195:04 pmRNSHolding(s) in Company
26th Mar 20197:00 amRNSHolding(s) in Company
18th Mar 201911:29 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.